New vaccine studies offer fresh possibilities for treating and preventing several cancers.
For decades, researchers have explored whether vaccines could teach the body’s immune system to recognize and attack cancer cells. While early efforts faced many setbacks, recent research is offering new reasons for hope. A major clinical trial, headed by associate professor of oncology, Mark Yarchoan, and his team at the Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, has found a personalized experimental vaccine for melanoma showed improved outcomes for patients. The trial results have been published in the New England Journal of Medicine.
Elizabeth Jaffee, a longtime cancer vaccine researcher and deputy director of the Johns Hopkins Kimmel Cancer Center, has been involved in this work for decades. She and other researchers began exploring therapeutic cancer vaccines in the late 1980s. Unlike vaccines designed to prevent infections, these treatments are intended to help the immune system recognize cancer that is already present.
One early approach involved a vaccine known as GVAX. Developed through work by Jaffee and Daniel Laheru, the vaccine used genetically changed tumor cells to encourage an immune response. Early studies involving pancreatic cancer showed that vaccination could bring groups of immune cells into tumors. This was an important finding because pancreatic tumors are often difficult for the body’s defenses to attack.
Other research at Johns Hopkins helped explain how vaccines might work better when paired with treatments that change the immune system’s response. Scientists advanced the study of PD-1 checkpoint inhibitors, which help remove some of the natural limits placed on immune cells. These treatments can allow the body’s defenses to remain active against cancer. Researchers are now studying how they can be combined with vaccines.

Advances in cancer genetics have also helped shape newer vaccine designs. Scientists learned that certain genetic changes in cancer cells create unusual proteins that are not found in healthy tissue. These proteins, known as neoantigens, can give the immune system something specific to recognize and attack.
Personalized cancer vaccines are built around those differences. Researchers study a patient’s tumor to identify its unique mutations, then develop a vaccine designed to trigger immune cells against those targets. The treatment may be paired with checkpoint inhibitors to help those immune cells keep working.
Johns Hopkins researchers are now testing similar approaches in several other forms of cancer. A 2024 study led by Yarchoan combined a personalized vaccine with pembrolizumab, an immune-based treatment, in people with hepatocellular carcinoma, the most common type of liver cancer. Another study led by Johns Hopkins researchers found responses in people with fibrolamellar carcinoma, a rare form of liver cancer that often affects teenagers and young adults.
Some of the work is also focused on preventing cancer before it develops. Jaffee and Neeha Zaidi are leading studies of an experimental vaccine designed to target changes in the KRAS gene. These changes are found in more than 90% of pancreatic cancers and may appear a decade or longer before the disease is diagnosed.
In one small study involving twenty people considered at increased risk for pancreatic cancer, the experimental vaccine produced an immune response in 90% of participants. Cancer-fighting immune cells remained detectable for as long as two years. None of the participants developed pancreatic cancer during the follow-up period. However, the study was small, and longer research involving more people is needed before researchers can determine whether the experimental vaccine can prevent the disease.
The team now hopes to test these promising results out on a larger population. Should they encounter similar findings, this could be a big step in the right direction when it comes to preventing the deadly disease.
Sources:
Experimental vaccines aim to treat and prevent aggressive cancers
Vaccines in cancer treatment and prevention: the time is now
A new experimental vaccine targets rogue genes linked to 90 percent of pancreatic cancers


Join the conversation!